Sutro Biopharma Dirección
Dirección controles de criterios 4/4
El CEO de Sutro Biopharma's es Bill Newell , nombrado en Jan 2009, tiene una permanencia de 15.25 años. compensación anual total es $3.04M, compuesta por 21.8% salario y 78.2% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.44% de las acciones de la empresa, por valor de $1.15M. La antigüedad media del equipo directivo y de la junta directiva es de 2.1 años y 4.8 años, respectivamente.
Información clave
Bill Newell
Chief Executive Officer (CEO)
US$2.1m
Compensación total
| Porcentaje del salario del CEO | 32.2% |
| Permanencia del CEO | 15.3yrs |
| Participación del CEO | 0.4% |
| Permanencia media de la dirección | 2.2yrs |
| Promedio de permanencia en la Junta Directiva | 4.9yrs |
Actualizaciones recientes de la dirección
Recent updates
Bearish: Analysts Just Cut Their Sutro Biopharma, Inc. (NASDAQ:STRO) Revenue and EPS estimates
Apr 02
The Market Doesn't Like What It Sees From Sutro Biopharma, Inc.'s (NASDAQ:STRO) Revenues Yet
Mar 28Sutro Biopharma, Inc.'s (NASDAQ:STRO) Price Is Right But Growth Is Lacking After Shares Rocket 43%
Dec 19Is Sutro Biopharma (NASDAQ:STRO) Using Debt In A Risky Way?
Aug 24Is Sutro Biopharma (NASDAQ:STRO) Using Too Much Debt?
Feb 10An Intrinsic Calculation For Sutro Biopharma, Inc. (NASDAQ:STRO) Suggests It's 47% Undervalued
Jan 12Sutro Biopharma: Partnership Progress Warrants Exposure
Aug 16New Forecasts: Here's What Analysts Think The Future Holds For Sutro Biopharma, Inc. (NASDAQ:STRO)
Aug 11Sutro Biopharma GAAP EPS of -$0.55, revenue of $28.1M
Aug 08Sutro to get $10M payment from Merck after first patient dosed in collaboration trial
Jul 26Is Sutro Biopharma (NASDAQ:STRO) Using Too Much Debt?
May 02Sutro; A Biotech To Watch With A Catalyst Rapidly Approaching
Dec 27Is Sutro Biopharma (NASDAQ:STRO) A Risky Investment?
Dec 26Sutro Biopharma initiated buy at H.C. Wainwright citing ADC candidates
Jun 18Industry Analysts Just Made A Sizeable Upgrade To Their Sutro Biopharma, Inc. (NASDAQ:STRO) Revenue Forecasts
May 09Is Sutro Biopharma (NASDAQ:STRO) Using Debt In A Risky Way?
May 07Sutro Biopharma EPS misses by $0.04, beats on revenue
May 07Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$115m |
| Dec 31 2023 | US$2m | US$687k | -US$107m |
| Sep 30 2023 | n/a | n/a | -US$172m |
| Jun 30 2023 | n/a | n/a | -US$143m |
| Mar 31 2023 | n/a | n/a | -US$130m |
| Dec 31 2022 | US$3m | US$663k | -US$119m |
| Sep 30 2022 | n/a | n/a | -US$123m |
| Jun 30 2022 | n/a | n/a | -US$134m |
| Mar 31 2022 | n/a | n/a | -US$114m |
| Dec 31 2021 | US$6m | US$625k | -US$106m |
| Sep 30 2021 | n/a | n/a | -US$127m |
| Jun 30 2021 | n/a | n/a | -US$79m |
| Mar 31 2021 | n/a | n/a | -US$43m |
| Dec 31 2020 | US$2m | US$554k | -US$32m |
| Sep 30 2020 | n/a | n/a | US$13m |
| Jun 30 2020 | n/a | n/a | -US$17m |
| Mar 31 2020 | n/a | n/a | -US$61m |
| Dec 31 2019 | US$4m | US$497k | -US$56m |
| Sep 30 2019 | n/a | n/a | -US$42m |
| Jun 30 2019 | n/a | n/a | -US$40m |
| Mar 31 2019 | n/a | n/a | -US$38m |
| Dec 31 2018 | US$9m | US$482k | -US$35m |
| Sep 30 2018 | n/a | n/a | -US$49m |
| Jun 30 2018 | n/a | n/a | -US$40m |
| Mar 31 2018 | n/a | n/a | -US$30m |
| Dec 31 2017 | US$703k | US$468k | -US$20m |
Compensación vs. Mercado: La compensación total ($USD2.13M) de Bill está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD1.64M).
Compensación vs. Ingresos: La compensación de Bill ha sido consistente con los resultados de la empresa en el último año.
CEO
Bill Newell (65 yo)
15.3yrs
Permanencia
US$2,129,980
Compensación
Mr. William J. Newell, also known as Bill, J.D. has been the Chief Executive Officer and Director of Sutro Biopharma, Inc. since February 2009. He served as Independent Director at Vaxcyte, Inc. since Nove...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | 15.3yrs | US$2.13m | 0.41% $ 1.4m | |
| Chief Scientific Officer | less than a year | US$1.63m | 0% $ 0 | |
| Chief Medical Officer | 1.3yrs | US$2.34m | 0.030% $ 103.8k | |
| President & COO | less than a year | US$1.43m | 0.052% $ 179.8k | |
| Founder | no data | sin datos | sin datos | |
| CFO & Secretary | 11.3yrs | US$2.08m | 0.13% $ 454.7k | |
| Chief Technical Operations Officer | less than a year | sin datos | 0.039% $ 135.2k | |
| General Counsel | 3.2yrs | sin datos | sin datos | |
| Chief People & Communications Officer | 16.3yrs | US$1.30m | 0.10% $ 355.0k | |
| Chief Portfolio Strategy & Alliance Officer | no data | sin datos | 0.017% $ 60.8k | |
| Vice President & Controller | no data | sin datos | sin datos |
2.2yrs
Permanencia media
60.5yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de STRO se considera experimentado (2.1 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | 15.3yrs | US$2.13m | 0.41% $ 1.4m | |
| Independent Chair of the Board | 4.9yrs | US$173.11k | 0% $ 0 | |
| Independent Director | 4.3yrs | US$138.11k | 0% $ 0 | |
| Independent Director | 10.3yrs | US$138.11k | 0.069% $ 239.9k | |
| Independent Director | 14.8yrs | US$140.11k | 0.027% $ 95.7k | |
| Member of Scientific Advisory Board | 1.3yrs | US$1.53m | 0.12% $ 427.6k | |
| Chair of the Scientific Advisory Board | 4yrs | sin datos | sin datos | |
| Independent Director | 5.8yrs | US$133.11k | 0% $ 0 | |
| Independent Director | 7.3yrs | US$152.11k | 0% $ 0 | |
| Co-Chair of Clinical Advisory Board & Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of the Clinical Advisory Board | 4yrs | sin datos | sin datos | |
| Independent Director | 2.5yrs | US$150.28k | 0% $ 0 |
4.9yrs
Permanencia media
65yo
Promedio de edad
Junta con experiencia: La junta directiva de STRO se considera experimentada (4.8 años de antigüedad promedio).